These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 18723549)

  • 21. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
    Hiles JJ; Kolesar JM
    Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.
    Di Fiore F; Rigal O; Ménager C; Michel P; Pfister C
    Br J Cancer; 2011 Dec; 105(12):1811-3. PubMed ID: 22095228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
    Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
    Lacouture ME; Reilly LM; Gerami P; Guitart J
    Ann Oncol; 2008 Nov; 19(11):1955-61. PubMed ID: 18550575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
    Kitajima K; Takahashi S; Maeda T; Yoshikawa T; Ohno Y; Fujii M; Miyake H; Fujisawa M; Sugimura K
    Eur J Radiol; 2012 Sep; 81(9):2060-5. PubMed ID: 21724350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
    J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract]   [Full Text] [Related]  

  • 27. Do the results of the new trials change the standard treatment of metastatic renal cell cancer?
    Mulder SF; van Spronsen DJ; De Mulder PH
    Onkologie; 2007 May; 30(5):260-4. PubMed ID: 17460422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapy for metastatic RCC--questions remain.
    Breau RH; Leibovich BC
    Nat Rev Urol; 2009 Nov; 6(11):580-1. PubMed ID: 19890336
    [No Abstract]   [Full Text] [Related]  

  • 29. [New therapeutic regimes in metastasic renal-cell carcinoma].
    Bierer S; Hertle L; Nitschmann S
    Internist (Berl); 2008 Jan; 49(1):114-7. PubMed ID: 18704353
    [No Abstract]   [Full Text] [Related]  

  • 30. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN; Flaherty KT
    Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract]   [Full Text] [Related]  

  • 31. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
    Riesenbeck LM; Bierer S; Hoffmeister I; Köpke T; Papavassilis P; Hertle L; Thielen B; Herrmann E
    World J Urol; 2011 Dec; 29(6):807-13. PubMed ID: 21153827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New therapeutic options for renal cell carcinoma.
    Stadler W
    Clin Adv Hematol Oncol; 2006 Jun; 4(6):429-30. PubMed ID: 16981664
    [No Abstract]   [Full Text] [Related]  

  • 33. Managing side effects of angiogenesis inhibitors in renal cell carcinoma.
    Grünwald V; Heinzer H; Fiedler W
    Onkologie; 2007 Oct; 30(10):519-24. PubMed ID: 17890892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.
    Feinberg BA; Jolly P; Wang ST; Fortner B; Scott J; Gilmore J; Neary MP; Duh MS
    Med Oncol; 2012 Jun; 29(2):786-94. PubMed ID: 21479699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
    Wong MK; Jarkowski A
    Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
    Barrascout E; Medioni J; Scotte F; Ayllon J; Mejean A; Cuenod CA; Tartour E; Elaidi R; Oudard S
    Bull Cancer; 2010; 97():29-43. PubMed ID: 20418202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health policy: The UK 'postcode lottery' in renal cell carcinoma.
    Larkin J; Gore M
    Nat Rev Urol; 2009 Dec; 6(12):636-8. PubMed ID: 19956190
    [No Abstract]   [Full Text] [Related]  

  • 38. Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.
    King CR
    ONS News; 2006; 21(8 Suppl):57-8. PubMed ID: 16925154
    [No Abstract]   [Full Text] [Related]  

  • 39. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
    Bukowski RM
    Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
    [No Abstract]   [Full Text] [Related]  

  • 40. [Angiogenesis and renal cell carcinoma].
    Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
    Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.